JV MY1
Alternative Names: JV-MY1Latest Information Update: 22 Sep 2022
Price :
$50 *
At a glance
- Originator JeniVision
- Class Eye disorder therapies
- Mechanism of Action Beta adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myopia
Most Recent Events
- 11 Aug 2022 Preclinical trials in Myopia in USA (Ophthalmic) (JeniVision pipeline, August 2022)